SCYNEXIS to Join the 2024 Maxim Healthcare Summit
SCYNEXIS, Inc. (NASDAQ: SCYX) is excited to share its participation in an important event—the Maxim Healthcare Virtual Summit. The event features a fireside chat during which David Angulo, M.D., President and Chief Executive Officer of SCYNEXIS, will address both the innovative work being done at the company and the broader challenges within the biotech sector.
Event Overview and Expectations
Scheduled for October 17, this summit will provide a platform for discussions around pressing topics related to healthcare and biotechnological advancements. Attendees can expect insights and critical updates about SCYNEXIS's ongoing projects aimed at addressing difficult-to-treat infections that often resist available therapies.
Fireside Chat Insights
During the fireside chat at 11:30 A.M. ET, Dr. Angulo will highlight the company's commitment to pioneering antifungal treatments. This session promises to be informative for investors and stakeholders as SCYNEXIS continues to innovate in a field that shows increasing challenges due to drug resistance.
Maxim Healthcare Virtual Summit Details
The Maxim Healthcare Virtual Summit aims to bring together experts and organizations to share knowledge and strategies. This event, held online, allows for greater accessibility for participants from various locations. Here are the essential details:
- Format: Fireside chat
- Date: October 17, 2024
- Time: 11:30 A.M. ET
- Location: Virtual
Innovative Approaches in Treating Infections
SCYNEXIS is known for its groundbreaking work in developing innovative antifungal therapies. One of its key platforms is the “fungerps” platform, which has garnered attention for its efficacy in combating challenging infections. Ibrexafungerp, the first drug from this platform, was licensed to GSK and received FDA approval in June 2021 for treating vulvovaginal candidiasis. Additionally, it has been approved for reducing the risk of recurrent infections.
Future Developments on the Horizon
With ongoing investigations into the efficacy of ibrexafungerp for life-threatening invasive fungal infections in hospital settings, SCYNEXIS is committed to expanding its offerings. The company is also working on other antifungal compounds, including SCY-247, which is currently in pre-clinical development.
Contact Information for Investor Relations
For those interested in further information or follow-up discussions post-summit, SCYNEXIS encourages reaching out via their investor relations contact:
Irina Koffler
LifeSci Advisors
Tel: (646) 970-4681
Email: ikoffler@lifesciadvisors.com
Frequently Asked Questions
What is SCYNEXIS's main focus area?
SCYNEXIS specializes in developing innovative antifungal therapies, particularly targeting drug-resistant infections.
Who is representing SCYNEXIS at the Summit?
Dr. David Angulo, the President and CEO of SCYNEXIS, will represent the company during the fireside chat.
When will the Maxim Healthcare Virtual Summit take place?
The summit is scheduled for October 17, 2024, at 11:30 A.M. ET.
How can investors learn more about SCYNEXIS?
Investors can learn more by attending the virtual summit, visiting the company’s website, or contacting the investor relations representative.
What potential advancements are SCYNEXIS working on?
The company is investigating the ongoing efficacy of ibrexafungerp for various complex infections and developing new antifungal compounds.